Sinomab Bio B Sustainability Profile
Sinomab Bio B, also known as Sinomab Bioscience, is a prominent biopharmaceutical company headquartered in Hong Kong. Founded in 2016, the company has rapidly established itself in the biotechnology sector, focusing on the development of innovative therapies for autoimmune diseases and cancer. With a strong operational presence in Asia and expanding into global markets, Sinomab Bio B is recognised for its unique monoclonal antibody products, which leverage advanced technologies to enhance efficacy and safety. The company has achieved significant milestones, including successful clinical trials that underscore its commitment to addressing unmet medical needs. Sinomab Bio B's strategic position in the biopharmaceutical landscape is marked by its dedication to research and development, making it a key player in the industry.
DitchCarbon Score
How does Sinomab Bio B's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sinomab Bio B's score of 32 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sinomab Bio B's reported carbon emissions
In 2022, Sinomab Bio B reported total carbon emissions of approximately 4,618,000 kg CO2e. This figure includes Scope 1 emissions of about 58,000 kg CO2e, primarily from stationary combustion and fugitive emissions, and Scope 2 emissions of approximately 4,537,000 kg CO2e, mainly from purchased electricity and steam. Additionally, the company recorded Scope 3 emissions of around 23,000 kg CO2e, with business travel contributing the majority. Sinomab Bio B has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 emissions to near zero by 2025. This target reflects a proactive approach to mitigating its carbon footprint and aligns with industry standards for climate action. The company’s emissions data is not cascaded from any parent organization, indicating that these figures are independently reported. Overall, Sinomab Bio B is taking significant steps towards sustainability, with clear targets for emission reductions in the near term.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|
| Scope 1 | 6,802.8 | 0,000.0 | 00,000 | 00,000 |
| Scope 2 | 1,672,797.6 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | 00,000 |
How Carbon Intensive is Sinomab Bio B's Industry?
How Carbon Intensive is Sinomab Bio B's Location?
Sinomab Bio B's Scope 3 Categories Breakdown
Their carbon footprint includes supplier sustainability and value chain emissions data across Scope 3 categories, with "Business Travel" being the largest emissions source at 91% of Scope 3 emissions.
Top Scope 3 Categories
Sinomab Bio B's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sinomab Bio B has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
